JPRN-jRCT2080222143未知1 期
A Phase 1 study on single oral dose administration of ONO-2160/CD in healthy adult male subjects and Parkinson's disease patients
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 42 人开始时间: 2013年7月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Healthy adult part
- •1. : BMI >=18.5, <25.0
- •Age : 20 to 45 years
- •Parkinson's disease patient part
- •1. Patients who have been diagnosed with Parkinson's Disease according to the clinical diagnosis criteria of UK Parkinson's Disease Society Brain Bank
- •2. Patients who have been administered levodopa/carbidopa hydrate combination tablets without prescription change within 28 days in prior to the study drug administration in the Period 1
- •Age : 20 to 74 years
- •Sex : male and female
排除标准
- •Healthy adult part
- •1. A volunteer who has developed acute gastrointestinal symptoms (e.g. diarrhea, nausea, heart burn) within 7 days in prior to the study drug administration, or a volunteer who is observed with these gastrointestinal symptoms on a daily basis.
- •Parkinson's disease patient part
- •1. A patient whose medical history, physical findings, laboratory test results can suggest parkinsonism from other causes than Parkinson's Disease
- •2. A patient who has received surgical treatments for Parkinson's Disease such as stereotactic neurosurgery, or who is planned with surgical treatments during the study period
研究者
相似试验
尚未招募
不适用
A Phase I study to evaluate a single oral dose of SRT2379 on the endotoxin induced inflammatory response in healthy male subjectsDoor endotoxine veroorzaakte inflammatie reactieInflammationinnate immunesystem10002252NL-OMON36662Sirtris Pharmaceuticals, Inc.16
未知
1 期
A Phase 1 Study of ONO-2160/CDParkinson's diseaseJPRN-jRCT2080222651ONO PHARMACEUTICAL CO.,LTD.34
进行中（未招募）
不适用
A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinomaPatients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinomaMedDRA version: 14.1Level: LLTClassification code 10014745Term: Endometrial carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024396-12-ITOVARTIS FARMA140
进行中（未招募）
1 期
BKM120 as second-line therapy in advanced endometrial cancerEUCTR2010-022015-19-BEovartis Pharma Services AG161
进行中（未招募）
不适用
A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma - NDEUCTR2010-022015-19-ITOVARTIS FARMA140